Почетна › Множен миелом › Колорадо › Denver
Клинички испитувања за Множен миелом во Denver, CO
27 студии за Множен миелом бараат учесници на локации во и околу Denver (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Се регрутираФаза 3
- Research Site, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Се регрутираФаза 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Се регрутираФаза 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Се регрутираФаза 1
- Research Site, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Се регрутираФаза 1
- Colorado Blood Cancer Institute, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Се регрутираФаза 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Се регрутираФаза 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Се регрутираФаза 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Се регрутираФаза 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Се регрутираФаза 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Се регрутираФаза 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Се регрутираФаза 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Се регрутираФаза 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Се регрутираФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Се регрутираФаза 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Се регрутираФаза 1
- Colorado Blood Cancer Institute, Denver
Испитувања за Множен миелом во други градови
- New York City, NY60 студии
- Boston, MA42 студии
- Atlanta, GA42 студии
- Houston, TX38 студии
- Durham, NC37 студии
- Nashville, TN32 студии
- Rochester, MN24 студии
- St. Louis, MO24 студии
- Columbus, OH24 студии
- Baldwin Park, CA23 студии
- Edison, NJ22 студии
- Chicago, IL22 студии
Други студии во Denver
- Метастатски карцином29 студии
- Рак на дојка29 студии
- Рак на бели дробови со не-мали клетки27 студии
- Колоректален карцином23 студии
- Меланом19 студии
- Рак на простата19 студии
- Рак (сите типови)18 студии
- Карцином на јајниците16 студии
- Рак на бели дробови16 студии
- Рак на ендометриумот15 студии
- Не-Хочкин лимфом14 студии
- Карцином на панкреасот13 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.